Oncology Corporate Profile
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. CBL0137 is under development by Incuron, LLC, a joint venture based in the Russian Federation that was founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Cleveland BioLabs, Inc. conducts business in the United States and in the Russian Federation through its wholly and majority owned operating subsidiaries. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia for Medical Research.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|entolimod||toll-like receptor 5 (TLR5)||Colorectal cancer||I|
|mobilan||oncolytic virus||Prostate cancer||I|
|entolimod||toll-like receptor 5 (TLR5)||Various cancer types||I|
View additional information on product candidates here »
3/17/2017 04:00 pm
3/14/2017 06:05 pm
2/28/2017 06:00 pm
2/22/2017 09:02 pm
2/22/2017 09:01 pm
[Marketwired] - Cleveland BioLabs, Inc. today reported financial results and development progress for the fourth quarter and year ended December 31, 2016.
12/7/2016 04:02 pm